Current Report Filing (8-k)
18 Enero 2022 - 8:31AM
Edgar (US Regulatory)
0001500123
false
Item 9 Labs Corp.
DE
0001500123
2022-01-18
2022-01-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report: January 18, 2022
ITEM
9 LABS CORP.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
000-54730
|
|
96-0665018
|
|
(State of other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
2727
N 3rd Street, Suite
201, Phoenix
AZ
85004
(Address of principal executive offices and zip code)
1-833-867-6337
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a -12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d -2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e -4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company. ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
|
|
|
|
|
|
|
Item 7.01.
|
Regulation FD Disclosure.
|
Attached hereto as
Exhibit 99.1 is a press release we issued on January 18, 2022, announcing fiscal year 2021 financial results.
|
Item 9.01
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
ITEM 9 LABS CORP.
|
|
|
|
|
|
Dated: January
18, 2022
|
By:
|
/s/ Robert
Mikkelsen
|
|
|
|
Robert Mikkelsen
|
|
|
|
Chief Financial Officer
|
Item 9 Labs (CE) (USOTC:INLB)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Item 9 Labs (CE) (USOTC:INLB)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
